First-Line SSRI Selection for Adults
Sertraline or citalopram/escitalopram are the preferred first-line SSRIs to initiate in adults without contraindications, based on their favorable tolerability profiles and minimal drug-drug interaction potential.
Primary Recommendation
Sertraline (starting dose 25-50 mg daily, maximum 200 mg daily) is the optimal first choice because it is well tolerated and has less effect on metabolism of other medications compared to other SSRIs 1. This makes it particularly advantageous in patients taking multiple medications or those at risk for drug interactions.
Citalopram (starting dose 10 mg daily, maximum 40 mg daily) or escitalopram (starting dose 10 mg daily, maximum 20 mg daily) are excellent alternatives as they are well tolerated and have the least effect on cytochrome P450 isoenzymes, resulting in lower propensity for drug interactions 1.
Alternative First-Line Options
Fluoxetine (starting dose 10 mg every other morning, maximum 20 mg daily): The only FDA-approved SSRI for depression in children and adolescents, and has demonstrated safety in pregnancy 1, 2. However, it is activating with a very long half-life, and side effects may not manifest for weeks 1. This long half-life can be advantageous for patients with adherence concerns but problematic when switching medications.
Paroxetine (starting dose 10 mg daily, maximum 40 mg daily): Less activating but more anticholinergic than other SSRIs 1. It should generally be avoided in older adults due to anticholinergic effects 1. It is also associated with higher risk of discontinuation syndrome and has been linked to increased risk of suicidal thinking compared to other SSRIs 1.
SSRIs to Avoid as First-Line
Fluvoxamine should not be used as first-line therapy due to greater potential for drug-drug interactions, particularly with alprazolam and triazolam, and its twice-daily dosing requirement (starting 50 mg twice daily, maximum 150 mg twice daily) 1.
Critical Safety Considerations
Monitoring Requirements
Close monitoring is essential during the first few months of treatment, particularly for clinical worsening, suicidality, and unusual behavioral changes 1. This is especially important during dose adjustments.
Start at lower doses and titrate slowly to minimize activation, anxiety, and other initial adverse effects 1. Starting SSRIs at higher doses increases the risk of deliberate self-harm and suicide-related events 1.
Common Adverse Effects
All SSRIs share typical side effects including sweating, tremors, nervousness, insomnia or somnolence, dizziness, gastrointestinal disturbances, and sexual dysfunction 1. Nausea is particularly common with citalopram and duloxetine 1.
Drug Interactions
Avoid combining SSRIs with monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome 1.
Exercise caution when combining with other serotonergic medications, including tramadol, meperidine, dextromethorphan, and certain over-the-counter products 1.
Citalopram requires special attention as it may cause QT prolongation at doses exceeding 40 mg daily and should be avoided in patients with long QT syndrome 1.
Discontinuation
All SSRIs must be tapered slowly when discontinued to avoid withdrawal syndrome, which is characterized by dizziness, fatigue, myalgias, gastrointestinal symptoms, and sensory disturbances 1. This is particularly important for shorter-acting SSRIs like paroxetine, sertraline, and fluvoxamine 1.
Special Populations
Older Adults
- Preferred agents include citalopram, escitalopram, and sertraline due to favorable adverse effect profiles 1.
- Start at approximately 50% of the standard adult starting dose and titrate more slowly 1.
- Avoid paroxetine and fluoxetine in older adults due to greater anticholinergic effects and risk of agitation/overstimulation, respectively 1.
Adolescents
- Fluoxetine is the only FDA-approved SSRI for depression in children and adolescents 1.
- Escitalopram is FDA-approved for adolescents aged 12 years and older 1.
- Lower effective dosages are generally required compared to adults 1.
Treatment Duration
Continue treatment for 4-12 months after a first episode of major depressive disorder 1. The probability of recurrence is approximately 50% after one episode, 70% after two episodes, and 90% after three episodes, so patients with recurrent depression may benefit from prolonged treatment 1.